NEW YORK (GenomeWeb) – In vitro diagnostics developer EDP Biotech said today it has signed a deal with Luminex to develop, market, and sell a blood-based colorectal test using the xMAP technology. Terms of the deal were not disclosed.
Called ColoPlex, the inexpensive blood test uses multiplexed immunoassay technology and machine learning to detect early state colorectal cancer and precancerous polyps.
Luminex’s bead-based xMAP technology allows EDP Biotech to look at up to 50 proteins from a single blood sample. Combined with data analytics, this allows the firm to detect protein profiles associated with precancerous polyps and early-stage colorectal cancer. “Our goal is to give physicians a new tool to help their patients when it matters the most,” said Eric Mayer, CEO of EDP.
Read full article on GenomeWeb 360Dx
